Mosquito bites carry key vaccine for malaria
Source: Agencies |
July 31, 2009, Friday
|
Print Edition
Print Edition
IN a daring experiment in Europe, scientists used mosquitoes as flying needles to deliver a "vaccine" of live malaria parasites via their bites.
The results were astounding: Everyone in the vaccine group acquired immunity to malaria; everyone in a non-vaccinated group did not, and developed malaria when exposed to the parasites later.
The study was only a small proof-of-principle test, and its approach is not practical on a large scale. However, it shows that scientists may finally be on the right track to developing an effective vaccine against one of mankind's top killers. A vaccine that uses modified live parasites just entered human testing.
"Malaria vaccines are moving from the laboratory into the real world," Dr Carlos Campbell wrote in an editorial accompanying the study in yesterday's New England Journal of Medicine. He works for PATH, the Program for Appropriate Technology in Health, a Seattle-based global health foundation.
Malaria kills nearly a million people each year, mostly children under five and especially in Africa. Infected mosquitoes inject immature malaria parasites into the skin when they bite; these travel to the liver where they mature and multiply. They then enter the bloodstream and attack red blood cells - the phase that makes people sick.
People can develop immunity to malaria if exposed to it many times. The drug chloroquine can kill parasites in the final bloodstream phase, when they are most dangerous.
Scientists tried to take advantage of these two factors, by using chloroquine to protect people while gradually exposing them to malaria parasites and letting immunity develop.
They assigned 10 volunteers to a "vaccine" group and five others to a comparison group. All were given chloroquine for three months, and exposed once a month to about a dozen mosquitoes - malaria-infected ones in the vaccine group and non-infected mosquitoes in the comparison group.
That was to allow the "vaccine" effect to develop. Next came a test to see if it works.
All 15 stopped taking chloroquine. Two months later, all were bitten by malaria-infected mosquitoes. None of the 10 in the vaccine group developed parasites in their bloodstreams; all five in the comparison group did.
The study was done in a lab at Radboud University in Nijmegen, the Netherlands.
The results were astounding: Everyone in the vaccine group acquired immunity to malaria; everyone in a non-vaccinated group did not, and developed malaria when exposed to the parasites later.
The study was only a small proof-of-principle test, and its approach is not practical on a large scale. However, it shows that scientists may finally be on the right track to developing an effective vaccine against one of mankind's top killers. A vaccine that uses modified live parasites just entered human testing.
"Malaria vaccines are moving from the laboratory into the real world," Dr Carlos Campbell wrote in an editorial accompanying the study in yesterday's New England Journal of Medicine. He works for PATH, the Program for Appropriate Technology in Health, a Seattle-based global health foundation.
Malaria kills nearly a million people each year, mostly children under five and especially in Africa. Infected mosquitoes inject immature malaria parasites into the skin when they bite; these travel to the liver where they mature and multiply. They then enter the bloodstream and attack red blood cells - the phase that makes people sick.
People can develop immunity to malaria if exposed to it many times. The drug chloroquine can kill parasites in the final bloodstream phase, when they are most dangerous.
Scientists tried to take advantage of these two factors, by using chloroquine to protect people while gradually exposing them to malaria parasites and letting immunity develop.
They assigned 10 volunteers to a "vaccine" group and five others to a comparison group. All were given chloroquine for three months, and exposed once a month to about a dozen mosquitoes - malaria-infected ones in the vaccine group and non-infected mosquitoes in the comparison group.
That was to allow the "vaccine" effect to develop. Next came a test to see if it works.
All 15 stopped taking chloroquine. Two months later, all were bitten by malaria-infected mosquitoes. None of the 10 in the vaccine group developed parasites in their bloodstreams; all five in the comparison group did.
The study was done in a lab at Radboud University in Nijmegen, the Netherlands.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
